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            Amendments from Version 1
The updated version clarifies aspects of anti-tuberculous and 
anti-retroviral therapy, answers reviewer questions regarding the 
ancillary DILI study, and describes how brain imaging is managed 
outside of the ancillary imaging study. All reviewer comments are 





Mycobacterium tuberculosis causes approximately 10.4 million 
new cases of tuberculosis and 1.5 million deaths annually, with 
an additional 0.4 million deaths in individuals co-infected with 
human immunodeficiency virus (HIV)1. Tuberculous meningitis 
(TBM) is the most severe form of tuberculosis, killing around 
30% of all sufferers despite appropriate anti-tuberculosis 
chemotherapy2. TBM is especially common in young children 
and in those with advanced immunodeficiency secondary to HIV, 
and is characterised by a slowly progressive meningo-encephalitis 
with necrotising granulomatous inflammation predominantly 
affecting the basal meninges.
Treatment of TBM
Rifampicin, isoniazid, pyrazinamide and ethambutol are rec-
ommended in current international guidelines for the treatment 
of drug-susceptible TBM, in adults with or without HIV, with 
treatment recommended for 9–12 months3,4. The treatment of drug 
resistant TBM is more challenging. Adjunctive anti-inflammatory 
treatment with corticosteroids (dexamethasone) has been shown 
to improve survival in TBM, in predominantly HIV-uninfected 
individuals in a small number of trials5.
Complications of TBM
Neurological complications of TBM
Hydrocephalus, stroke, and tuberculoma formation are important 
complications of TBM2. They generally present within the first 
3 months of treatment and can be fatal if not detected and treated 
quickly. Little evidence exists to help guide the management 
of these complications, which are common in HIV-infected and 
uninfected TBM patients of all ages2. In untreated HIV-infected 
patients with TBM, contemporaneous anti-tuberculosis treatment 
and anti-retroviral therapy (ART) can result in neurological 
inflammatory complications secondary to ART-driven IRIS6. 
Tuberculoma and spinal radiculomyelitis are the commonest 
IRIS complications described.
Drug induced liver injury (DILI)
Hepatitis is the most common drug-induced serious adverse 
event associated with anti-tuberculosis treatment, occurring in 
approximately 10% of HIV-uninfected and 20% of HIV-infected 
patients7. Almost all episodes occur in the first 3 months of 
anti-tuberculosis therapy, a critical time in TBM treatment. 
Rifampicin, isoniazid, and pyrazinamide can all cause DILI, although 
determining which drug is responsible in individual patients 
can be difficult. Anti-tuberculosis DILI is widely defined as 
elevation of blood transaminase concentrations ≥3 times the upper 
limit of normal (ULN) with symptoms, or ≥5 times the ULN 
without symptoms4. US Centers for Disease Control and Prevention 
guidelines for pulmonary tuberculosis suggest stopping all anti-
tuberculosis drugs in DILI until transaminase concentrations 
have returned to <2 times the ULN, followed by sequential 
re-introduction4, however this approach is probably unsafe in 
those with TBM. We have previously shown that interruptions 
in first-line anti-tuberculosis chemotherapy for any reason 
is an independent risk factor for death from TBM8. The suggested 
concentration thresholds for stopping anti-tuberculosis drugs are 
not evidence-based. The optimal strategy for managing DILI 
in TBM is uncertain9. The majority of asymptomatic rises in 
transaminases (even those >5 times the ULN) will resolve 
spontaneously, therefore higher thresholds for stopping therapy, 
perhaps up to 10 times ULN, may be more appropriate. The 
optimal order and method of drug re-introduction is unknown, and 
no randomised comparisons have ever been published within the 
context of TBM treatment.
Dexamethasone induced adrenal suppression
Iatrogenic administration of exogenous corticosteroids is 
associatedwith adrenal suppression, and the sudden cessation 
of treatment can lead to Addisonian crises which can be life- 
threatening. For this reason it is common practice to prescribe 
corticosteroids in tapering doses, to allow recovery of the adrenal 
cortex during the treatment period. Thus, by the time the 
corticosteroid is finished, normal endogenous cortisol production 
will have resumed with no risk of Addisonian crisis. Whether 
the use of corticosteroids in the doses prescribed in infectious 
diseases are associated with significant adrenal suppression is not 
clear and has not been investigated.
HIV-associated TBM
Co-treatment of HIV and tuberculosis
HIV infection increases the risk of an individual infected 
with M. tuberculosis developing TBM, complicates treatment, 
and substantially worsens outcome10–12. Co-treatment of HIV 
and tuberculosis is complex because of the adherence demands 
of multidrug therapy for two infections, drug-drug interactions 
between rifampicin and ART, overlapping side effect profiles 
of anti-tuberculosis drugs and ART, and the frequency of IRIS. 
The optimal strategy for starting ART in TBM is unclear.
Use of adjunctive dexamethasone
How corticosteroids confer a survival benefit, and whether 
they do so in HIV-infected patients with TBM, remains uncer-
tain. In TBM dexamethasone may reduce the early intracerebral 
inflammatory response, prevent hydrocephalus infarction and 
tuberculoma formation, and reduce the incidence of neurological 
IRIS. Dexamethasone may reduce the risk of DILI and thereby 
improve outcome by enabling uninterrupted anti-tuberculosis treat-
ment. The current evidence-base for using adjunctive corticoster-
oids for the treatment of HIV-associated TBM is restricted to 98 
adults recruited to a trial in Vietnam8,13. This trial randomised a 
total of 545 subjects (98 of them HIV-positive) and reported an 
overall reduction in 9-month mortality due to dexamethasone 
from 41.3% (112/271) to 31.8% (87/274) (hazard ratio of time 
to death 0.69; 95% confidence interval (CI) 0.52–0.92, P=0.01). 
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While there was no clear evidence of treatment effect heterogene-
ity according to HIV status, the number of included HIV-infected 
subjects was low and the observed benefit in that subgroup was 
smaller: 61.4% (27/44) in the dexamethasone group died, com-
pared to 68.5% (37/54) in the placebo group (hazard ratio of 
time to death 0.86; 95% CI 0.52–1.41; P=0.55). On the basis of 
these data most international guidelines cautiously recommend 
dexamethasone should be given for HIV-associated TBM, but 
all acknowledge the paucity of evidence and the need for 
additional controlled trial data.
Study hypotheses
Neurological complications are both common and devastat-
ing in TBM. Dexamethasone may reduce complications aris-
ing from an early intracerebral inflammatory response, including 
neurological IRIS. Dexamethasone has been shown to improve 
survival in HIV-unaffected individuals with TBM. Our primary 
hypothesis is that adjunctive dexamethasone increases 
survival from TBM in HIV co-infected adults. The secondary 
hypothesis is that current guidelines for the management of 
anti-tuberculosis DILI in those with TBM result in the premature 
interruption of rifampicin and isoniazid (the critical active drugs 




Our primary aim is to determine whether dexamethasone is 
a safe and effective addition to the first 6–8 weeks of anti- 
tuberculosis treatment of TBM in patients with HIV with 
dexamethasone duration depending on Medical Research Council 
(MRC) grade (Supplementary File 1) at the start of treatment. In 
making this assessment we not only determine whether dexame-
thasone improves survival, but also whether it lengthens the time 
to new neurological events, IRIS, drug-related adverse events, 
opportunistic infections, and disability assessed by the modified 
Rankin scale (Table 1). We will follow participants for 24 months 
to assess longer-term neurological outcomes and the incidence 
of HIV-associated malignancy in the two treatment arms.
Secondary aim
Our secondary aim is to investigate alternative management 
strategies in a subset of patients who develop DILI that will 
enable the safe continuation of rifampicin and isoniazid therapy 
whenever possible.
Design and setting
ACT HIV is a parallel group, randomised (1:1), double blind, 
placebo-controlled multi-centre Phase III trial, comparing dex-
amethasone versus placebo for 6–8 weeks in addition to standard 
anti-tuberculosis and antiretroviral treatment. The trial will 
be set in two hospitals in Ho Chi Minh City, Vietnam and two 
hospitals in Jakarta, Indonesia. The trial will enrol 520 HIV-infected 
adults (≥ 18 years old) admitted to participating hospitals with 
a suspected diagnosis of TBM, as judged by the attending 
physician, and requiring immediate anti-tuberculosis treatment. 
Doctors making the diagnosis of TBM will all be senior 
physicians specialising in either infectious diseases or tuberculosis 
and lung diseases. All will receive additional diagnostic training 
and follow a diagnostic standard operating procedure. This trial 
schema is shown in Figure 1.
An ancillary DILI strategy study will perform a randomised 
comparison of management strategies in DILI early in anti- 
tuberculosis treatment (the intensive phase). We will perform an 
open, randomised comparison of three management strategies 
with the aim of demonstrating which strategy results in the least 
interruption in rifampicin and isoniazid treatment. All patients 
enrolled in the main trial will be eligible to take part in this 
study, with the exception of those known to have TBM caused by 
isoniazid resistant or MDR M. tuberculosis.
Ancillary studies
Seven ancillary studies will be conducted within the ACT HIV 
trial. Some of the studies will only involve a subset of patients 
recruited at the Hospital for Tropical Diseases (HTD), Ho Chi Minh 
City, Vietnam. Ancillary studies 2, 3 and 7 will be retrospective 
data analyses. Ancillary study 4 and 5 will collect and review 
patient results as the trial progresses. For ancillary study 6 results 
will be fully analysed at the end of the trial, however laboratory 
values that may influence clinical care will be available to the 
clinical team as the trial progresses.
The studies are as follows:
 Ancillary study 1: A randomised comparison of management 
strategies in response to DILI (as above). (All patients.)
 Ancillary study 2: Host and bacterial genetic determinants 
of treatment response. We hypothesise that the LTA4H 
gene, and genes involved in related inflammatory pathways, 




1 Minor symptoms not interfering with lifestyle
2 Symptoms that lead to some restriction in lifestyle, but do not interfere with the patients ability to look after themselves
3 Symptoms that restrict lifestyle and prevent totally independent living
4 Symptoms that clearly prevent independent living, although the patient does not need constant care and attention.
5 Totally dependent, requiring constant help day and night.
6 Death
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Figure 1. Trial Schema (main trial).
TBM severity, and treatment response. We will also examine 
genetic variants associated with the development of DILI. 
(All patients.)
 Ancillary study 3: Impact of dexamethasone on CSF 
inflammation and gross cerebral pathology (assessed 
by serial brain magnetic resonance imaging (MRI)). 
We will investigate how dexamethasone influences the 
resolution of inflammatory markers in the CSF and the 
gross pathological consequences of TBM on the brain 
(hydrocephalus, stroke, and tuberculoma formation). (HTD 
patients only.)
 Ancillary study 4: Influence of diabetes mellitus on 
presentation and response to treatment. We will investigate 
whether diabetes mellitus influences clinical presentation 
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and CSF inflammatory phenotype (linking with ancillary 
study 2), and how it impacts upon treatment outcomes. 
(All patients.)
 Ancillary study 5: Influence of Strongyloides infection on 
presentation and response to treatment. We will determine 
whether Strongyloides co-infection alters clinical and/or 
CSF inflammatory phenotype at TBM presentation 
(linking with ancillary study 2) and treatment response. 
(All patients.)
 Ancillary study 6: Pathophysiology and treatment of 
hyponatraemia and raised intracranial pressure. We will 
investigate the pathophysiology of TBM-associated hypo-
natraemia, enabling a better understanding of the causes 
of hyponatraemia, the relationship between plasma sodium 
and elevated intracranial pressure, and the best management 
of severe hyponatraemia. (HTD patients only.)
 Ancillary study 7: Dexamethasone induced adrenal 
suppression. We will investigate whether the use of 
corticosteroids in the doses prescribed in infectious diseases 
are associated with significant adrenal suppression. (HTD 
patients only.)
Endpoints
Primary endpoint – ACT HIV (main trial)
The primary endpoint of the main trial is overall survival, 
i.e. the time from randomisation to death, during a follow-up period 
of 12 months. Survivors known to be alive at 12 months will be 
censored at that time-point and subjects who withdrew or were 
lost to follow-up before 12 months will be censored at the date 
they were last known to be alive.
Primary endpoint – DILI strategy study
In the DILI strategy study the primary endpoint is the proportion 
of time in the 60 days following randomisation during which 
neither rifampicin nor isoniazid are given (or the subject is dead).
Secondary endpoints – ACT HIV (main trial)
The secondary endpoints of the main trial are as follows:
a)     Neurological disability at day 30 from randomisation, 
monthly until completion of anti-tuberculous drugs, 
and at months 12, 18 and 24. The main endpoint is the 
12-month assessment and subjects who died before 
12 months will be treated as having a score of 6 (‘dead’). 
Neurological disability will be assessed by the modified 
Rankin score (Table 1).
b)     Time to first new neurological event or death during a 
follow-up period of 12 months. A neurological event is 
defined as a fall in Glasgow Coma Score (GCS) by ≥2 
points for ≥2 days from the highest previously record-
ed GCS (including baseline), or the onset of any of the 
following clinical adverse events: cerebellar symptoms, 
focal neurological signs, or seizures.
c)     Time to neurological IRIS events from randomisation 
until 6 months. We will follow the International Network 
for the Study of HIV associated IRIS (INSHI) case 
definition of IRIS (14, Supplementary File 2). Rate of 
neurological IRIS is defined as the number of IRIS events 
divided by the observed person-time of follow-up in 
each treatment group. 
d)     Time to new acquired immunodeficiency syndrome 
(AIDS)-defining event (as per World Health Organisation 
classification) or death, during a follow up period of 
12 months.
e)     Time to HIV-associated malignancy from randomisa-
tion until 12 months. Rate of HIV-associated malignancy 
is defined as the number of events of the three major HIV-
associated malignancies (Kaposi sarcoma, high grade 
B-cell non-Hodgkin lymphoma and invasive cervical 
cancer) divided by the observed person-time of follow-up 
in each treatment group. 
f)     Serious adverse events until 12 months. Comparison of 
the frequency of serious adverse events between treatment 
groups will form an important part of the study analysis.
g)     Endpoints assessed at 24 months of follow up. All 
participants will continue to be followed up for 24 months 
and the following outcomes will be reported once this 
period has been completed for all participants: overall 
survival until 24 months, neurological disability at 
24 months, recurrence of TBM until 24 months, time to 
new AIDS defining event or death until 24 months, and 
rate of  HIV-related malignancy until 24 months.
Secondary endpoints – DILI strategy study
The secondary endpoints of the DILI strategy study are as 
follows:
a)     Development of acute liver failure (defined as new onset 
coagulopathy (International normalised ratio (INR)>1.5) 
and hepatic encephalopathy) after randomisation.
b)     ART interrupted due to drug-related injury.
c)     Time to new neurological event (defined as a fall in 
GCS of ≥2 points for ≥48 hours, new focal neurological 
sign, or new onset of seizures) or death from 
randomisation until the 12 month follow-up of the main 
trial.
d)     Overall survival, i.e. time to death from any cause, until 
the 12 month follow-up of the main trial.




Study participants for ACT HIV must be adults (aged 18 years 
or older), HIV-infected, with a clinical diagnosis of TBM 
(≥5 days of meningitis symptoms, and CSF abnormalities) and 
anti-tuberculosis chemotherapy either planned or started by the 
attending physician. Participants will be considered eligible 
for enrolment in this trial if they fulfil all the inclusion criteria 
and none of the exclusion criteria. TBM is a serious infection 
whose standard treatment requires hospitalisation. Therefore all 
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eligible participants will be treated in hospital, at least for the 
initial 3 weeks of their illness. Pregnant participants are eligible 
for enrolment. Participants with drug resistant TBM are an 
important sub group, and are eligible for enrolment into the main 
study (but not the DILI ancillary study).
Study participants for the DILI strategy study must be 
receiving first-line anti-tuberculosis drugs and fulfil the definition 
of drug-related liver injury: elevation of blood transaminase 
concentrations ≥3 times the ULN with symptoms and signs of 
hepatitis (vomiting, abdominal pain, jaundice), or ≥5 times the 
ULN or a rise in serum bilirubin >2.0mg/dL (>34 µmol/L) without 
symptoms4, and less than 90 days of anti-tuberculosis drugs given.
Exclusion criteria
Exclusion criteria for ACT HIV are:
a)     An additional brain infection (other than TBM) confirmed 
or suspected: positive CSF Gram or India Ink stain; 
positive blood or CSF Cryptococcal antigen test; cerebral 
toxoplasmosis suspected and attending physician wants 
to give anti-toxoplasmosis treatment with anti-tuberculosis 
treatment.
b)     More than 6 consecutive days of two or more drugs active 
against M. tuberculosis immediately before screening.
c)     More than 3 consecutive days of any type of orally or 
intravenously administered corticosteroid immediately 
before randomisation.
d)     Dexamethasone considered mandatory for any reason 
by the attending physician.
e)     Dexamethasone considered to be contraindicated for 
any reason by the attending physician.
f)     Patient has previously been randomised into this trial 
for a prior episode of TBM.
g)     Lack of consent from the participant or family member 
(if the participant is incapacitated by the disease).
Exclusion criteria for the DILI strategy study are:
a)    TBM known to be caused by isoniazid resistant or MDR 
M. tuberculosis or standard first-line anti-tuberculosis 
drugs unable to be given for any reason other than 
DILI.
b)    Signs of chronic liver disease of any cause (hepato-
splenomegaly, prolonged jaundice, caput medusa, spider 
angiomata, ascites, oedema).
c)    Lack of consent from the participant or family member 
(if the participant is incapacitated by the disease).
d)    Elevation of blood transaminase concentrations ≥3 times 
the ULN with symptoms and signs of hepatitis (vomiting, 
abdominal pain, jaundice), or ≥5 times the ULN or 
a rise in serum bilirubin >2.0mg/dL (>34 µmol/L) 
without symptoms at baseline (day 0).
Recruitment, retention and randomisation
Recruitment and retention
Recruitment activities will only occur in an inpatient hospital 
setting in participating hospitals. The target sample size of 520 
participants will be enrolled into the main trial, with an antici-
pated accrual rate of 4 years. Once discharged from hospital the 
participants will be contacted by phone to remind them of their 
next visit. In addition, patients who have missed a visit will be 
contacted by phone for a maximum of three times after which a 
maximum of three home visits can be conducted. All contact 
attempts will be recorded. As part of routine clinical care 
participants with suspected TBM will have an HIV test, a lumbar 
puncture, and a GeneXpert MTB/RIF test on CSF to assess the 
likelihood of M. tuberculosis infection and rifampicin resistance. 
When possible, participants will be screened for eligibility 
on the day their CSF results return and at the time the decision 
is made to start anti-tuberculosis chemotherapy for suspected/ 
confirmed TBM. The name and date of birth of every adult 
screened for the trial should be added to the site Screening and 
Randomisation Register, together with the allocated trial number 
if subsequently randomised, or the reason the participant 
was not randomised. We anticipate 100 ACT-HIV patients will 
consent to the ancillary DILI strategy study.
Randomisation
Randomisation to ACT HIV will be stratified by participat-
ing hospital/site and modified MRC TBM severity grade. The 
randomisation list will be computer-generated based on random 
permuted blocks with variable block size following Oxford Uni-
versity Clinical Research Unit (OUCRU) standard operating 
procedures. A 24h web-based randomisation service will be 
provided. The OUCRU biostatistician in charge of randomisa-
tion list preparation will set up statistical code to generate the 
randomisation list and transfer it to the Study Pharmacist. The 
Study Pharmacist will then change the random seed, i.e. the 
initialisation of the random numbers generator, in the statistical 
code in order to blind the biostatistician and then run the code to 
prepare the final randomisation list. The generated randomisation 
lists will be securely incorporated within the trial database. 
A reliable manual back-up system will also be available. Ran-
domisation to the three strategies for DILI will be 1:1:1 with 
stratification by initial randomisation (dexamethasone or placebo) 
and site. Authorised individuals will receive an allocated 




All participants and investigators will be blinded to the 
treatment allocation. OUCRU clinical trials unit (CTU) phar-
macists will create blinded drug packages (in fully made-up and 
labelled treatment packs) containing either active drugs or identical 
placebo sufficient for 6–8 weeks of treatment (dependent on the 
MRC grade of the participant) according to the prespecified 
randomisation list, and pre-ship them to the sites. After randomi-
sation, the ward or trial research nurse will take the completed 
prescription form to the site pharmacy; they will dispense the 
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trial-number specific pack containing the study drug. Unused 
drug will be returned to the site pharmacy if a participant with-
draws from treatment. In ancillary study 3 MRI brain images will 
be read by an independent neuroradiologist, blind to the 
treatment allocation and outcomes of the participant.
Unblinding
If, in the opinion of the local clinician, it is important 
for good clinical care to unblind treatment the documented 
request will be discussed with the site Principal Investigator (PI) 
and Chief Investigator (CI). If it is agreed that knowledge of 
treatment allocation is essential for the best management of 
the patient, the unblinding code will be provided by the study 
pharmacist holding the randomisation list at OUCRU CTU 
upon documented request from the CI. Generalised clinical 
deterioration is not sufficient for unblinding, given equipoise about 
the evidence base supporting the use of dexamethasone regardless 
of clinical severity. All instances of unblinding will be recorded 
and reported to the Data Monitoring Committee (DMC) and Trial 
Steering Committee (TSC).
Protocol treatment discontinuation
An individual participant may stop study drug early for any 
of the following reasons: Participant no longer believed to 
have TBM and all anti-tuberculosis treatment stopped; Con-
firmatory HIV tests are negative and HIV infection excluded; 
Unacceptable toxicity or adverse event; Intercurrent illness that 
prevents further treatment; Any change in the participant’s condi-
tion that justifies the discontinuation of treatment in the treating 
physicians opinion and after discussion with the site PI; Inad-
equate compliance with the protocol treatment in the judgement 




All participants will receive the standard of care anti-TB drugs 
and ART drugs according to respective national guidelines. 
In ART-naive patients, ARTs will be started 6–8 weeks after 
the start of anti-tuberculosis drugs. Study participants for the 
main trial will be randomised to receive either dexamethasone 
or placebo (investigational medicinal product (IMP)) as an extra 
medication for 6–8 weeks, dependent upon the severity of TBM 
disease (Table 2). Dexamethasone/placebo will be dispensed at 
randomisation from the site pharmacy in intravenous and oral 
(tablet) formulations. Placebo will be identical in appearance 
to active drug and dosed and dispensed in the same way. The 
study drug will be given to participants as early as possible in 
the treatment of TBM but no later than 7 days from the start of 
anti-tuberculosis treatment.
Participants for the DILI strategy study will be randomised 
to one of three strategies (Figure 2): Strategies are as follows:
1)     Observe: measure transaminases, bilirubin, and INR 
every 3 days; do not change/stop anti-tuberculosis 
drugs unless transaminases rise to ≥10x normal, or total 
bilirubin rises >2.5mg/dl (>43 µmol/L), or INR >1.5 
or symptoms of hepatitis worsen (nausea, vomiting, 
abdominal pain), in which case go to Strategy 3.
2)     Stop pyrazinamide (Z) alone. Observe, measuring 
transaminases, bilirubin, and INR every 3 days. If trans-
aminases do not fall to <5x ULN by day 5, or total 
bilirubin rises >2.5mg/dl (>43 µmol/L), or INR >1.5 
or symptoms of hepatitis worsen at any time (nausea, 
vomiting, abdominal pain), go to Strategy 3.
3)     Current standard of care (current US CDC guidelines4, 
Supplementary File 3).
Patients in the DILI study will undergo regular clinical and blood 
test monitoring, and there is a clear procedure to follow for 
moving patients from strategy 1 to strategy 3, or from strategy 
2 to strategy 3. We hypothesise that current guidelines for the 
management of anti-tuberculosis DILI result in the premature 
interruption of rifampicin and isoniazid (the critical active drugs 
in early therapy) in those with TBM and are thereby placing 
participants at risk of poor outcomes. Strategies 1 and 2 may 
demonstrate improved safety compared to strategy 3. However, 
regular clinical monitoring, and interim review by an independ-
ent data monitoring committee, will be in place to ensure safety 
of participants in case of any increased adverse events in any of 






Week 1 0.3 mg/kg/24 hrs IV 0.4 mg/kg/24 hrs IV
Week 2 0.2 mg/kg/24 hrs IV 0.3 mg/kg/24 hrs IV
Week 3 0.1 mg/kg/24 hrs IV 0.2 mg/kg/24 hrs IV
Week 4 3mg/24 hrs oral 0.1 mg/kg/24 hrs IV
Week 5 2mg/24 hrs oral 4 mg/24 hrs oral
Week 6 1 mg/24 hrs oral 3 mg/24 hrs oral
Week 7 Stop 2 mg/24 hrs oral
Week 8 1 mg/24 hrs oral
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Figure 2. Trial Schema (drug-induced liver injury strategy study).
DILI related interventions are conducted within the ACT HIV 
trial, but the DILI strategies (specifically arms 1 and 2, compared 
with the routine care arm 3) are not expected to increase adverse 
events. It is in fact anticipated that arm 1 (continue all 4 first line 
anti-TB drugs) and arm 2 (stop only pyrazinamide) of the DILI 
study will result in less adverse events due to the continuation 
of the best and most appropriate anti-TB drugs. Liver function 
tests will be closely monitored. DILI occurs more frequently in 
individuals with HIV therefore it is very important that DILI 
interventions are assessed in an HIV positive group, to avoid 
unnecessary cessation of first line anti-TB drugs if arms 1 and / 
or 2 are effective. From a safety perspective, if a patient develops 
DILI, prior randomisation to dexamethasone or placebo should 
not affect DILI in an adverse way.
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Anti-tuberculosis treatment
First line anti-tuberculosis treatment will follow current Vietnamese 
and Indonesian national guidelines. Rifampicin (10mg/kg/24 hrs; 
maximum 600mg), isoniazid (5mg/kg/24hrs; maximum 
300mg), pyrazinamide (25mg/kg/24hrs; maximum 2g) and 
ethambutol (20mg/kg/24 hrs; maximum 1.2g) will be given 
for at least the first 2 months of treatment, provided drug resist-
ance is not suspected or proven. Pyrazinamide will then be 
stopped and rifampicin, isoniazid and ethambutol (at the same 
doses) will then be given until at least 12 months anti-tuberculosis 
treatment in total has been given. Patients with visual complica-
tions will discontinue ethambutol and an alternative drug will 
be used in its place. The decision of which fourth drug to use 
will be made by the treating physician, and is not mandated 
by the trial. In practice this will be either a fluoroquinolone or 
streptomycin.
For TBM caused by isoniazid-resistant tuberculosis the attending 
physician should decide which option to take, dependent upon 
clinical circumstances. For participants with MDR tuberculo-
sis, second-line treatment should be given as soon as possible, 
following national guidelines and local policies.
Participants with abnormal liver function tests (LFTs) at 
screening are eligible to enter the main trial. These patients should 
be given standard first-line anti-tuberculosis treatment unless blood 
transaminase concentrations are ≥3 times the ULN with symp-
toms and signs of hepatitis (vomiting, abdominal pain, jaundice), 
or ≥5 times the ULN or a rise in serum bilirubin >2.0mg/dL 
(>34µmol/L) without symptoms. In these participants, initial 
anti-tuberculosis treatment should consist of levofloxacin, 
ethambutol, and an aminoglycoside (either kanamycin, amikacin 
or streptomycin). LFTs should be monitored every 3 days and 
rifampicin started as soon as blood transaminases are <5x the 
ULN and/or the symptoms and signs of hepatitis resolve. Once 
the participant is tolerating a rifampicin-containing regimen 
isoniazid can be introduced and, if isoniazid is tolerated, the 
aminoglycoside can be stopped. If pyrazinamide is not used 
in treatment, at least 12 months of anti-tuberculosis treatment 
must be given. Participants with liver dysfunction at the start 
of treatment that require modified initial anti-tuberculosis 
treatment regimens are ineligible for the DILI strategy study.
Anti-retroviral therapy
ART will be provided for all participants within the 
current Vietnamese and Indonesian national guidelines. ART 
in both Ho Chi Minh City and Jakarta is often commenced 
6–8 weeks after the start of anti-tuberculosis treatment, with the 
precise timing left to the discretion of the attending physician. 
Delays in starting ART of longer than 8 weeks are not encouraged. 
This practice is supported by our previous trial of immediate versus 
deferred ART in TBM and consistent with current local practice 
guidelines15. The optimal time to start ART in TBM is not known, 
depends upon TBM disease severity and CD4 count, and varies 
between centres regarding routine practice. Exactly when to start 
ART is decided upon by the treating physician. A patient with 
known HIV already on ART will continue this ART when they 
enter the trial, and during the trial. Whenever possible, patients 
will be treated with an efavirenz-containing regimen. When 
viral resistance to first line (NNRTI-based) ART is suspected, 
case-by-case decisions will be made with regard to HIV-RNA 
measurement, drug resistance testing, and composition and 
timing of second line HIV treatment and concurrent tuberculosis 
treatment, avoiding combined use of rifampicin and protease 
inhibitors because of strong drug interactions and high risk of 
toxicity16. Decisions on dose or schedule adjustments for these 
participants will be made on an individual basis, following the 
national and local guidelines. If DILI develops ART should 
not be stopped until all other management has been tried 
(including interrupting anti-tuberculosis drugs according to the 
randomised schedule). HIV specialists and liver specialists 
should be consulted at this point.
Prophylaxis for opportunistic infections
All participants will receive Pneumocystis jirovecii prophylaxis 
with co-trimoxazole according to national guidelines (CD4 
count <200 cells/mm3). In the DILI strategy study prophylactic 
co-trimoxazole and/or fluconazole should be stopped before 
all other drugs if DILI develops.
Use of concomitant medication
All other concomitant medications essential for participant 
management are permitted at enrolment, subject to the exclusion 
criteria of no contraindications to the use of dexamethasone 
in the judgement of the attending clinician. If use of a concomitant 
medication that cannot safely be used with dexamethasone 
becomes essential after randomisation, then the IMP should be 
stopped and the concomitant medication used without unblinding. 
Drugs which increase the risk of gastrointestinal bleeding, 
such as non-steroidal anti-inflammatory drugs (NSAIDS), should 
be used with caution. Any other oral or intravenously adminis-
tered corticosteroids are not permitted, unless deemed essential, 
in which case the study drug should be stopped and replaced by 
the chosen corticosteroid. The treatment of tuberculosis and HIV 
once the study drug has been stopped should be determined 
by national guidelines and the physician responsible for the care 
of the participant.
Management of neurological complications occurring after 
the start of anti-tuberculosis treatment
Neurological deterioration, manifest by falling conscious 
level or new focal neurological signs, is common after the start 
of treatment of TBM2. Common causes are hydrocephalus, 
stroke, tuberculomas, and hyponatraemia, and neurological events 
occurring within 2 months of starting ART may also be due 
to IRIS. Whenever possible, all patients with unexplained 
neurological deterioration should have either brain imaging with 
computed tomography (CT) or MRI. Corticosteroids are not rou-
tinely recommended for the treatment of hydrocephalus or stroke. 
Tuberculomas may cause significant peri-lesional inflammation 
and oedema and can manifest as new onset seizures, focal 
neurological deficit, or globally reduced consciousness. In these 
circumstances, most physicians recommend using corticosteroids. 
Therefore, if after clinical and neuroradiological review the 
attending physician believes a patient’s neurological deterio-
ration is due to tuberculoma(s), open-label dexamethasone is 
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recommended. Study drug should be stopped, if it still being given 
(without the need for unblinding), and high-dose intravenous dex-
amethasone (0.4mg/kg/24hrs) should be prescribed. The speed of 
dexamethasone reduction and the total duration of therapy should 
be determined on a case-by-case basis by the attending physician.
Management of IRIS
Untreated HIV-infected patients starting ART treatment for the 
first time after at least 2 weeks of anti-tuberculosis treatment will 
be at risk of developing neurological IRIS. A single randomised 
controlled trial demonstrated that corticosteroids reduced the 
need for hospitalisation and therapeutic procedures and hastened 
improvements in symptoms, performance, and quality of life 
in IRIS associated with non-neurological tuberculosis IRIS17. 
Therefore, in the absence of other data, if the criteria for 
IRIS are met, then we recommend the participant should 
be given open-label dexamethasone or prednisolone. If the par-
ticipant has IRIS with neurological involvement then intravenous 
dexamethasone 0.4mg/kg/24 hrs should be given. Oral 
prednisolone (following the published trial regimen17) should be 
given for non-neurological IRIS (prednisone 1.5mg/kg per day 
for 2 weeks, then 0.75mg/kg per day for 2 weeks). IRIS will be 
diagnosed if the participant meets the antecedent requirements, 
clinical IRIS criteria, and alternative explanations for the 
clinical deterioration are excluded if possible (Supplementary 
File 2). Cases where alternative diagnoses cannot be fully 
excluded because of limited diagnostic capacity should be regarded 
as “probable paradoxical tuberculosis-associated IRIS”. In these 
probable cases, should resolution of clinical or radiological 
findings of the suspected IRIS episode occur without a change 
in tuberculosis treatment or ART having been made, they 
could then be reclassified as ”paradoxical tuberculosis-associated 
IRIS” cases.
Data collection
The trial assessment schedule for ACT HIV is outlined in 
Table 3.
Clinical assessment
Clinical assessment will include conscious level by GCS, 
new or ongoing focal neurological deficit, clinical treatment 
response, all serious adverse events including new malignan-
cies and opportunistic infections, all adverse events of any grade 
leading to modification of anti-tuberculosis treatment or ART or 
their interruption/early discontinuation (and clinician-assessed 
likelihood of relationship of adverse event to dexamethasone), 
and adherence to drugs (study drug, anti-tuberculosis drugs and 
ART). Assessment of disability by the modified Rankin score 
will be performed at day 30 from randomisation, monthly until 
completion of anti-TB drugs, and at months 12, 18 and 24.
Inpatient assessment
The clinical team will record daily GCS and new focal 
neurology throughout the participant’s hospital admission. Par-
ticipants will be visited by one of the research team at screen-
ing, baseline, and at least every 3 days for the first 4 weeks of 
treatment (unless they are discharged or die before 4 weeks) 
and then at least every 7 days whilst they remain in hospital. 
Formal trial clinical assessments will occur on day 0, 3, 7, 10, 14, 
and weekly thereafter until discharge (+/- 1 day).
Outpatient assessment
After discharge clinical assessments will occur monthly 
until 12 months. Some of these assessments can be made by phone. 
Formal outpatient review will occur monthly (+/- 7 days) for 
at least the first 2 months following hospital discharge. The patient 
should have formal outpatient review at least every 2 months 
until month 12 after randomisation. Thereafter patients should be 
followed up by phone call at 15 months and 21 months and by 
formal outpatient review at 18 months and 24 months from 
randomisation.
HIV monitoring
HIV infection must be confirmed before entry to the study. 
Peripheral blood CD4 count and HIV viral load will be measured 
at baseline (routine counts taken within 2 weeks of study entry 
are acceptable), and CD4 count will be repeated at 60 days.
Liver function
Alanine transaminase (ALT) and bilirubin will be measured to 
evaluate liver toxicity every 7 days until discharge.
Additional blood tests
EDTA blood will be taken for hepatitis B surface antigen and 
hepatitis C antibodies, and serum will be stored for later DNA 
extraction where consent has been given. We will use the 
DNA to investigate novel genetic determinants of treatment 
response, including LTA4H genotype, and the development of 
DILI.
Glycosylated haemoglobin (HbA1c) and fasting blood sugar
HbA1c and fasting blood sugar will be measured at baseline 
and at 60 days from randomisation. This will enable determina-
tion of the frequency of undiagnosed diabetes in those present-
ing with TBM, assess diabetic control in those known to have 
diabetes, and evaluate the influence of dexamethasone and 
anti-tuberculosis treatment on diabetic control over the first 
60 days of TBM treatment. To enable more detailed phenotyping 
of diabetes we will also measure C-peptide and blood lipids at 
baseline and store plasma for future diabetes related auto-antibody 
testing.
Strongyloides
All enrolled participants will be tested for serological evidence 
of Strongyloides infection (past or latent infection) with stool 
examination for evidence of active infection at baseline and at 
60 days from randomisation. When infection is detected, treatment 
with ivermectin will be provided. High-dose corticosteroids 
can lead to re-activation of latent Strongyloides and hyperinfection 
syndrome. Stool will be examined for Strongyloides larvae on 
day 60 (end of study drug) to determine whether reactivation 
alters TBM treatment responses.
Synacthen test
We will compare adrenal responsiveness at 3 weeks after 
randomisation and at the end of study drug treatment (6 or 
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Table 3. ACT HIV trial assessment schedule.
            DAYS                             MONTHS
SCREENING 0 3 7 WEEkly uNtIl 
dISChaRGE









Clinical assessment (X) X X X X X X X X X X
Disability assessment X X X X X X
Chest X-ray (X) X X
Lumbar puncture (with 
paired plasma glucose) 






EDTA blood for genetic 
tests 
Full blood count 
CD4 count 
HIV viral load 






















Hepatitis C antibodies 











































Brain MRI X X X
SUBSET OF PARTICIPANTS RECRUITED TO HYPONATRAEMIA/ICP ANCILLARY STUDY (HTD Vietnam only)
24-hour fluid balance (X) X X X X
Plasma sodium
Plasma osmolality
X X X X
Urinary sodium 
Urinary osmolality
X X X X
Plasma cortisol X
Ultra-sound assessment 
of intravascular volume 
X X X X
Ultra-sound measurement 
of optic nerve sheath 
diameter
X X X X
SUBSET OF PARTICIPANTS RECRUITED TO ADRENAL SUPPRESSION ANCILLARY STUDY (HTD Vietnam only)
Synacthen test X (day 21) X
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8 weeks depending upon disease severity) in 100 consecutive 
patients using the short Synacthen test. The patient’s background 
cortisol level is measured by drawing 2mls of blood at 0900hrs. 
250mcg of Synacthen is then administered intravenously; 3ml 
samples of blood are taken at thirty minutes and sixty minutes 
to measure the cortisol level after this adrenal stimulation. 
Synacthen test will be repeated at day 60 after randomisation.
Lumbar puncture
Lumbar puncture should be performed, unless clinically 
contraindicated, as part of routine clinical care for the baseline 
assessment and on days 30 and 60 after randomisation to assess 
treatment response. Day 60 lumbar punctures are not routine 
practice in the Jakarta hospitals and will therefore not be man-
dated by the trial in these centres. Opening pressure should be 
measured, at least 5mls of CSF should be taken for mycobacterial 
investigations alone, and assessments of cell count and differ-
ential, protein, glucose (paired with serum), and lactate should 
also be performed on 1–2 mls of additional CSF. Ziehl Neelsen 
(ZN) stain, GeneXpert, and M. tuberculosis culture will be 
performed on all CSF taken. As part of an ancillary study 
of the impact of dexamethasone on CSF inflammation and gross 
cerebral pathology we will measure concentrations of a variety 
of inflammatory mediators in the CSF (leucocytes, cytokines, 
chemokines, and eicosanoids, for example) at baseline and on days 
30 and 60 after randomisation to determine how dexamethasone 
influences their expression.
Hyponatraemia and raised intracranial pressure
In the subset of participants enrolled to HTD, Ho Chi Minh 
City, Vietnam, we will investigate the pathophysiology of TBM-
associated hyponatraemia by serial assessments of fluid balance, 
paired plasma and urinary sodium and osmolality, and 
intravascular volume by Doppler ultrasound assessment of infe-
rior vena cava collapsibility index18,19. We will also use portable 
ultrasound to measure the optic nerve sheath diameter, which 
has been shown to be a reliable and non-invasive measure of 
raised intracranial pressure20,21. These additional measurements 
will be assessed at days 0, 3, and 7, and weekly until discharge. 
Plasma cortisol will be measured at day 0.
Imaging
Chest Xray will be performed at screening and on day 60 and 
12 months after randomisation. In the subset of participants 
enrolled to HTD, Ho Chi Minh City, Vietnam, we will perform 
brain imaging by MRI (or CT if the participant cannot tolerate 
an MRI) at baseline (+/- 7 days) and at 60 days (+/- 7 days) and 
at 12 months (-0/+1 month). At sites other than HTD, Ho Chi 
Minh City, Vietnam, brain imaging is performed based upon the 
routine care at that site. Brain imaging may not always be 
readily available, and this study does not mandate brain imaging 
for every patient. Brain imaging for suspected TBM is strongly 




Specific procedures will be followed when notifying and 
reporting adverse events (AEs) or adverse reactions (ARs). The 
definitions of the EU Directive 2001/20/EC Article 2 based 
on the principles of ICH good clinical practice (GCP) apply 
to this trial protocol. All AEs and ARs will be assessed as to 
whether they are serious or not. If the event is serious and not 
only related to TBM, or is fatal, then a serious adverse event 
(SAE) form must be completed and the OUCRU CTU noti-
fied within 24 hours. All AEs and ARs (serious and non-serious) 
should be graded using toxicity gradings.
Causality of all SAEs or serious adverse reactions (SARs) 
in relation to the trial therapy (dexamethasone) will be assessed. 
There are five categories: unrelated, unlikely, possible, probable, 
and definitely, related. If the causality assessment is unrelated 
or unlikely to be related, the event is classified as an SAE. 
If the causality is assessed as possible, probable or definitely 
related, then the event is classified as an SAR. If there is at least 
a possible involvement of the trial treatment (or comparator), 
the investigator must assess the expectedness of the event. An 
unexpected adverse reaction is one not previously reported in the 
current Summary of Product Characteristics (SPC) at the time 
the event occurred, or one that is more frequent or more severe 
than previously reported. If a SAR is assessed as being unex-
pected, it becomes a suspected unexpected serious adverse 
reaction (SUSAR). Investigators should always check the current 
version of the SPC.
Safety reporting
The OUCRU CTU is responsible for the reporting of SUSARs 
and other SARs to the regulatory authorities and the research 
ethics committees. The following events will be reported to the 
relevant authorities in Vietnam and Indonesia: All unexpected 
SAEs, all SAEs judged to be related or possibly related to 
the trial intervention, and all deaths. All SAEs will be reported 
to OxTREC (Oxford Tropical Research Ethics Committee) 
in the annual review form and to the DMC in accordance to the 
DMC charter. An independent DMC will oversee the safety of 
the trial.
Interim analyses
Interim analyses are planned after 6 and 12 months of 
recruitment and yearly thereafter until the completion of the 
trial but the DMC has the authority to modify the frequency of 
interim analyses. At these interim analyses, the DMC will receive 
a report including unblinded summaries of baseline character-
istics, the primary endpoint, and adverse events by treatment 
arm. The DMC will also review data from those enrolled into 
the DILI strategy ancillary study, in particular the incidence of 
acute hepatic failure in each of the management strategy arms.
Statistical analysis
Sample size justification – ACT HIV (main trial)
A previous trial of dexamethasone included 545 subjects 
with TBM and reported a reduced risk of death by 9 months 
associated with dexamethasone (hazard ratio of death 0.69 (95% 
CI 0.52–0.92)) and no evidence of heterogeneity with respect to 
HIV status though the number of HIV-infected patients was low 
(98 subjects) and none of them received antiretroviral therapy8. 
A recent TBM trial of intensified TBM treatment reported 
9-month mortality in 349 HIV-infected patients of 40% in both 
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study arms and all subjects received dexamethasone7. Few 
additional deaths are expected to occur between months 9 and 
1215. Assuming a target hazard ratio of 0.69 (corresponding to 
a mortality reduction from 52% to 40% in favour of dexam-
ethasone), a total of 229 deaths need to be observed during the 
12-month follow-up duration to obtain a power of 80% at the 
two-sided 5% significance level according to Schoenfeld’s 
formula. To achieve this and allowing for a 5% loss-to-follow-up, 
a total of 520 HIV-infected subjects with TBM need to be 
recruited into the main trial.
Sample size justification – DILI strategy study
A review of 36 subjects who interrupted rifampicin and 
isoniazid because of clinical hepatitis or jaundice events from our 
previous trial7 gave the following data: the median (IQR) onset 
date of the DILI was 50 (15–84) days from initiation of anti- 
tuberculosis treatment, the median (IQR) duration of the rifampicin 
and isoniazid interruption was 16 (12–24) days, and 12 sub-
jects subsequently died (8 of them within 60 days). Of note, the 
duration of the treatment interruption was <30 days for 32 (89%) 
of the 36 subjects and the remaining 4 subjects never re-started 
rifampicin or isoniazid but continued to receive alternative 
anti-tuberculosis treatment for >100 days. For the DILI strategy 
study we hypothesise that strategies 1 and 2 will result in 
a relative reduction in the duration of the treatment interruption 
of 50% for subjects with interruptions <30 days, but that 
they do not affect longer interruptions (as the corresponding 
subject might have permanent intolerance to rifampicin and 
isoniazid) or mortality. Based on simulations of hypothetical trials 
using re-sampling from the data described above, the hypothesised 
treatment effect, and the Wilcoxon rank sum test for analysis, 
we determined that the power to detect such an effect size with 
a sample size of at least 50 subjects per arm is >85%. Of note, 
given this is an ancillary and essentially ‘opportunistic’ study, we 
have chosen a liberal (i.e. not multiplicity corrected) two-sided 
significance level of 5% for each of the two primary compari-
sons of strategies 1 and 2, respectively, versus strategy 3. A total 
of 170 participants will be recruited to the DILI sub-study. The 
DILI sub-study has been powered for the combined analysis of 
ACT HIV (we anticipate 100 ACT HIV patients will consent 
to the DILI sub-study) and LAST ACT (a linked RCT of dex-
amethasone in HIV-uninfected adults with TBM stratified by 
LTA4H genotype, from which we anticipate 70 patients will 
enter the DILI sub-study)22.
Analysis populations – ACT HIV (main trial)
Patients in the main trial will be analysed according to their 
randomised arm as an intention-to-treat (ITT) analysis. In addi-
tion, the primary endpoint will be analysed in the per-protocol 
population, which will exclude the following patients: patients 
with a final diagnosis other than TBM, major protocol violations 
and those receiving less than 1 week of administration of the 
randomised study drug for reasons other than death. Published 
diagnostic criteria23 will be applied to all enrolled participants 
at the end of the study when all mycobacterial culture results 
are available (Supplementary File 4). The criteria will sub-divide 
all cases into definite, probable and possible TBM, and those 
with an alternative diagnosis.
For the primary analyses of the main trial the second ran-
domisation in the DILI strategy study will be ignored and the 
estimated dexamethasone treatment effect can thus be interpreted 
as an average effect across these three management strategies. 
We believe that this is justified because only approximately 
100 (19%) subject are expected to be enrolled in the nested 
trial with roughly similar numbers from both arms, because the 
efficacy of the different management strategies is unlikely to 
depend on whether the patient received dexamethasone or not 
as it tests a very different intervention, and because the antici-
pated effect of the management strategy on survival is relatively 
small. However, in a supplementary analysis, we will also 
compare the primary endpoint between the treatment policies 
“dexamethasone treatment plus standard of care management of 
drug-related liver injury” vs. “placebo treatment plus standard of 
care management of drug-related liver injury” using an inverse 
probability weighting based analytical framework24.
Analysis populations – DILI strategy study
All patients in the DILI strategy study will be analysed 
according to their randomised arm as an ITT analysis. The two 
primary comparisons are the comparisons of strategies 1 and 
2, respectively, versus strategy 3 (with tests conducted at the 
unadjusted two-sided 5% significance level) and comparisons 
between strategies 1 and 2 will be exploratory only.
Primary endpoint analysis – ACT HIV (main trial)
The primary endpoint of the main trial is overall survival, 
i.e. time from randomisation to death, during 12 months of fol-
low-up. Overall survival will be analysed with a Cox proportional 
hazards regression model with treatment as the only co-variate 
and stratification by TBM MRC severity grade at enrolment (I, 
II, or III) and country (Vietnam or Indonesia). The primary effect 
measure is the resulting hazard ratio comparing dexamethasone vs. 
placebo with a corresponding two-sided 95% confidence interval 
and p-value. The significance level of the associated two-sided 
test will be set to 5%. Kaplan-Meier plots and explicit survival 
estimates at 3, 6, 9, and 12 months of follow-up will also be 
calculated for the full populations and in the subgroups defined 
by TBM disease severity and country separately. The propor-
tional hazards assumption will be formally tested based on scaled 
Schoenfeld residuals and visually assessed by a plot of the 
scaled Schoenfeld residuals versus transformed time. In case of 
a significant test, a formal comparison of the absolute risk of 
death at 12 months between the two groups will also be per-
formed (using a Wald-type test based on Kaplan-Meier estimates at 
12 months and associated standard errors using Greenwood’s 
formula).
The homogeneity of the treatment effect on overall survival 
across subgroups will be assessed by subgroup analyses and for-
mal tests of interaction between treatment and the following 
grouping variables: TBM MRC severity grade at enrolment (I, II, 
or III), country (Vietnam or Indonesia), drug resistance pattern 
(MDR-TB or rifampicin mono-resistance, isoniazid resistant 
non-MDR, no or other resistance), ART status at enrolment (ART 
naive, ≤3 months of ART, >3 months of ART), and CD4 cell 
count at enrolment. To obtain an adjusted treatment effect 
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estimate and to assess the effect of other covariates on survival, 
the primary endpoint will also be modelled using a multivariable 
Cox proportional hazards regression model including the 
following covariates (in addition to the treatment group): TBM 
MRC severity grade at enrolment, country, drug resistance 
pattern, ART status and CD4 cell count at enrolment. Multiple 
imputation will be used to handle missing covariates.
Primary endpoint analysis – DILI strategy study
For the analysis of the primary endpoint of the DILI strategy 
study, the non-parametric Wilcoxon rank sum test will be used 
for pairwise comparisons. An additional adjusted analysis (with 
adjustment for the initial randomisation, HIV-status, and the time 
from initial randomisation to the second randomisation) will 
be also be performed treating the outcome as an ordinal outcome 
and using a proportional odds logistic regression model (which 
can be interpreted as an extension of the Wilcoxon rank sum test). 
Secondary endpoint analysis
For ACT HIV, neurological disability (assessed by modified 
Rankin scale) at 12 months will be compared between the two 
arms with a proportional odds logistic regression model with 
the treatment assignment as the main covariate and adjustment 
for TBM MRC severity grade, and country. The result will be sum-
marised as a cumulative odds ratio with corresponding 95% CI 
and p-value. Patients with a missing 12-month disability assess-
ment will be excluded from the main analysis but an alternative 
analysis based on multiple imputation (including disability 
assessments at earlier time points in the imputation model) will 
also be performed. Secondary time-to-event endpoints (time to 
neurological event or death, time to new AIDS event or death) 
will be analysed in the same way as the primary endpoint. The 
number of IRIS and HIV-associated malignancy events in each 
group will be summarised and the event rate calculated in each 
arm. Comparisons of the rates between the treatment arms 
will be based on a cause-specific proportional hazards model 
of the time to the first IRIS event (or HIV-associated malignancy, 
respectively) or death with treatment as the only covariate.
Analysis of adverse events
The number of patients with any adverse events and specific 
events, respectively, will be summarised and informally compared 
between the two treatment arms based on Fisher’s exact test. The 
total number of adverse event episodes per patient will also be 
summarised and informally compared based on a quasi-Poisson 
regression model with treatment as the only covariate. The 
following subgroups of adverse events will also be separately 
summarised: grade 3&4 adverse events; serious adverse events; 
serious adverse events possibly, probably, or definitely related 
to the study drug; adverse events leading to TB treatment or 
ART interruptions. Grade 3&4 laboratory abnormalities will 
be summarised in the same way as clinical adverse events.
Adverse events due to DILI will be recorded for the DILI study 
but also for the primary intervention (dexamethasone or placebo). 
An increased number of adverse events in DILI arms 1 and 2 
are not expected, but if they do occur these adverse events will 
be associated with both the DILI randomisation strategy and 
for the primary intervention arm in which they occurred.
Analysis of ancillary studies
Ancillary studies will be analysed within the same groups as 
allocated based on the dexamethasone intervention. Allocation 
to the intervention (dexamethasone or placebo) is important for 
each sub study, given the effect of corticosteroids on inflamma-
tory pathways, diabetes control, Strongyloides infection, raised 
intracranial pressure and adrenal suppression. DILI study patients 
will be analysed in their DILI arm, but an additional adjusted 
analysis (with adjustment for the initial randomisation) will also 
be performed. 
Baseline descriptive analyses
Baseline characteristics will be summarised as median (lower 
and upper quartiles) for continuous data and frequency (percent-
age) for categorical data. The amount of missing data for each 
baseline characteristic will also be displayed. 
Ethical considerations
Treatment
All participants will receive the best available treatment of 
tuberculosis and HIV, following local and national guidelines. 
Corticosteroids are commonly prescribed drugs and there is 
widespread experience and expertise concerning their safe use. 
The choice (dexamethasone), dose, route of administration and 
duration of study treatment follows the international guidance 
for the treatment of HIV-uninfected participants with TBM. 
Previous trials have demonstrated the safety of this or similar 
regimens. In particular, adjunctive corticosteroids were not 
associated  with increased gastro-intestinal bleeding in a meta- 
analysis of all published TBM trials, although participants in this 
trial will be carefully monitored for this event. There is a 
possibility dexamethasone may increase the risk of HIV-associated 
malignancies, which will also be monitored closely in the trial.
Confidentiality
Participants’ confidentiality will be maintained throughout the 
trial. Participants will be assigned a trial identification number 
and this will be used on case report forms (CRFs); participants 
will not be identified by their name. The investigator will 
keep securely a participant trial register showing identification 
numbers, surnames and date of birth. The unique trial number will 
identify all laboratory specimens, case record forms, and other 
records and no names will be used, in order to maintain confi-
dentiality. Data submitted to OUCRU CTU and samples sent to 
central testing facilities will be identified only by the trial 
number and participant initials.
Consent
Written informed consent must be obtained in order to 
enter into the trial and be randomised. If a participant lacks 
capacity, written consent must be obtained from a person with 
responsibility (e.g. family member/relative), in their own language 
before enrolment by the site PI or an appropriately trained 
doctor. All potential participants (or their families) will be given 
a participant information sheet clearly listing the risks and 
benefits of the trial. All potential participants (or their families) will 
be able to discuss participation with their consulting doctor who 
will be able to address questions not covered or arising from the 
participant information sheet. Incapacitated adults with TBM will 
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be eligible to enter the trial. These adults have more severe disease 
and therefore may benefit most from adjunctive dexamethasone. 
We anticipate around 70% of participants with TBM will 
lack capacity at the start of treatment. An option will be given to 
patients to enrol in the main study, but not the DILI strategy study.
If consent is provided by a relative, the participant should 
be consulted and consent recorded if and when they have the 
capacity to do so. If they are happy to remain in the trial, the 
participant should complete a participant consent form at this time. 
If they wish to withdraw from the trial, no further trial-related 
procedures will be performed, but data to this point would be 
used in analysis. Data from any participant who dies before 
regaining capacity (but whose family member has provided 
consent) will be included in analysis.
Protocol violations
All deviations from protocol will be addressed in source 
documents and reported to the OUCRU CTU.
Withdrawing from the trial
A participant (or their relative) is free to refuse to participate 
in or withdraw from all or any aspect of the trial, at any time 
and for any reason. If a participant chooses to discontinue their 
trial treatment they should always be followed up (providing 
they are willing) and they should be encouraged not to leave 
the whole trial. If they do not wish to remain on trial follow-up 
however, their decision must be respected and the participant 
will be withdrawn from the trial. Participants may change their 
minds about stopping trial follow-up at any time and re-consent 
to participation in the trial.
Data collection and storage
Clinical data and clinical laboratory data will be entered into 
CliRes, a 21 CFR Part 11-compliant data capture system pro-
vided by the OUCRU IT department. The data system includes 
password protection and internal quality checks, such as auto-
matic range checks, to identify data that appear inconsistent, 
incomplete, or inaccurate. Trial data will be recorded onto paper 
CRFs and entered into CliRes. The participants will be identified 
by a unique trial specific number and/or code in any database. 
The name and any other identifying detail will not be included 
in any trial data electronic file. CRFs, clinical notes and admin-
istrative documentation will be kept in a secure location and 
held for 15 years after the end of the trial. Clinical information will 
not be released without written permission, except as necessary 
for monitoring, auditing and inspection purposes. Electronic 
data will be kept for at least 20 years at the OUCRU CTU.
SPIRIT checklist
A SPIRIT checklist for this trial protocol is attached 
(Supplementary File 5).
Trial Committees
A Trial Management Group (TMG) will be formed to 
conduct the day-to-day management of the trial at the OUCRU 
CTU. This will include the CI, Head of OUCRU CTU, Trial 
Statistician, Clinical Project Manager, Trial Manager, Data 
Manager and Jakarta trial coordinator. The group will meet at least 
once per month, although may meet more or less often as required. 
The TSC has membership from the TMG plus independent 
members (Professor Nicholas Paton (Infectious Diseases Phy-
sician and Clinical Trialist, National University of Singapore, 
Singapore), Professor Ben Marais (Senior Tuberculosis 
Researcher and Trialist, University of Sydney, Australia), 
Dr Truong Huu Khanh (Infectious Diseases Physician, Paedi-
atric Hospital Number 1, Ho Chi Minh City, Vietnam)), includ-
ing the Chair (Professor Robert Wilkinson (Honorary Professor 
and Director Wellcome Centre for Infectious Diseases Research 
in Africa, University of Cape Town, South Africa)). The 
role of the TSC is to provide overall supervision for the trial and 
provide advice through its independent chair. The ultimate deci-
sion for the continuation of the trial lies with the TSC. The DMC 
(Professor Sarah Walker (DMC Chair, Senior Statistician 
and Clinical Trialist, MRC Clinical Trials Unit, University 
College London), Professor Graeme Meintjes (Senior Infec-
tious Diseases/HIV Physician, University of Cape Town, 
South Africa) and Professor Nina Ruslami (Senior TBM Cli-
nician and Researcher, Universitas Padjadjaran, Bandung, 
Indonesia)), will advise the TSC and can recommend premature 
closure or reporting of the trial, or that recruitment be discon-
tinued or modified. The DMC is independent from the sponsor. 
Access to interim data and results will be confidential and strictly 
limited to the DMC and results (except for the recommenda-
tion) will not be communicated to the outside and/or clinical 
investigators involved in the trial. This trial is sponsored by 
The University of Oxford (Contact: University of Oxford, 
Research Services, University Offices, Wellington Square, 
Oxford OX1 2JD, Tel +44 (0) 1865 282585).
Data dissemination
Manuscripts arising from the trial will, wherever possible, 
be submitted to peer-reviewed journals which enable Open Access 
via UK PubMed Central (PMC) within six months of the offi-
cial date of final publication. In line with research transparency 
and greater access to data from trials OUCRU’s clinical trials 
are registered at ClinicalTrials.gov and a data sharing policy is 
in place. Data exchange complies with Information Governance 
and Data Security Policies in all of the relevant countries.
Discussion
TBM remains the most severe form of tuberculosis, and 
is especially common in those infected with HIV. Whether cor-
ticosteroids confer a survival benefit in HIV-infected patients 
remains uncertain, with the current evidence base for using 
corticosteroids in this context restricted to 98 adults recruited 
to a trial in Vietnam8,13. The ACT HIV trial aims to determine 
whether dexamethasone is a safe and effective addition to the first 
6–8 weeks of anti-tuberculosis treatment of TBM. ACT HIV will 
be performed in parallel with a randomised double blind placebo 
controlled trial of adjunctive dexamethasone in HIV-uninfected 
Vietnamese adults stratified by Leukotriene A4 hydrolase (LTA4H) 
genotype (LAST ACT, clinical trial registration NCT03100786)22. 
Both trials will recruit to seven ancillary studies, including a 
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study to investigate alternative management strategies in a subset 
of patients who develop DILI, enabling safe continuation of 
rifampicin and isoniazid therapy whenever possible. In recruit-
ing the target 520 patients into the main trial, this trial has the 
opportunity to also study the following: Host and bacterial genetic 
determinants of treatment response; Impact of dexamethasone 
on CSF inflammation and gross cerebral pathology; Influence of 
diabetes mellitus on presentation and response to treatment; Influ-
ence of Strongyloides infection on presentation and response 
to treatment. Pathophysiology and treatment of hyponatraemia 
and raised intracranial pressure; Dexamethasone induced 
adrenal suppression. These data will be valuable in guiding 
the management of adjunctive corticosteroid therapy in 
HIV-infected individuals.
Trial status
Trial protocol version 1.4, 1st August 2017. Estimated recruitment 
start date 1st June 2017. Estimated time for recruitment is 4 years.
Ethical statement
The trial has ethics approval from the Oxford Tropical 
Research Ethics Committee (approval number 36-16), the Eth-
ics Committees of the Hospital for Tropical Diseases (approval 
number CS/ND/16/37) and Pham Ngoc Thach Hospital (approval 
number CS/PT/16/07), the Vietnam Ministry of Health, and Fac-
ulty of Medicine University of Indonesia (17-01-0066). Protocol 
version 1.4 has ethics approval from the Oxford Tropical Research 
Ethics Committee, the Ethics Committee of the Hospital for 
Tropical Diseases, the Ethics Committee of Pham Ngoc Thach 
Hospital, the Vietnam Ministry of Health, and the Faculty of 
Medicine University of Indonesia.
Informed consent will be obtained for all study participants.
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Due to the linked nature of this trial, some sections of this 
protocol also form part of the linked RCT LAST ACT (Trial 
registration number: NCT03100786), which has also been 
submitted to Wellcome Open Research22. LAST ACT is a parallel 
group, randomised (1:1), double blind, placebo-controlled, multi-
centre Phase III non-inferiority trial, comparing dexamethasone 
versus placebo for 6–8 weeks in addition to standard anti- 
tuberculosis treatment in HIV-uninfected patients with TBM 
stratified by LTA4H genotype. The 7 ancillary studies in ACT 
HIV are also recruited to through the LAST ACT trial. As such the 
hypotheses, design, methods, sample size justification; analysis 
plans and endpoints of these ancillary studies will also be 
described in the LAST ACT trial, and will appear identically here. 
ACT HIV follows the same OUCRU protocols and local / national 
guidelines as LAST ACT, therefore randomisation, blinding 
and unblinding procedures, adverse event and safety reporting, 
ethics and confidentiality sections also appear identically here for 
ACT HIV as for the LAST ACT trial.
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The exclusion criteria includes:
“b) More than 6 consecutive days of two or more drugs active against immediately before screening.
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